Matches in Wikidata for { <http://www.wikidata.org/entity/Q57580460> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q57580460 description "article scientifique publié en 2017" @default.
- Q57580460 description "article" @default.
- Q57580460 description "im Mai 2017 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57580460 description "wetenschappelijk artikel" @default.
- Q57580460 description "наукова стаття, опублікована в травні 2017" @default.
- Q57580460 name "Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy" @default.
- Q57580460 name "Initial efficacy of anti-lymphocyte activation gene-3" @default.
- Q57580460 type Item @default.
- Q57580460 label "Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy" @default.
- Q57580460 label "Initial efficacy of anti-lymphocyte activation gene-3" @default.
- Q57580460 prefLabel "Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy" @default.
- Q57580460 prefLabel "Initial efficacy of anti-lymphocyte activation gene-3" @default.
- Q57580460 P1433 Q57580460-0C18CFB7-ABB8-4DB7-A503-E12B5FBB47CF @default.
- Q57580460 P1476 Q57580460-F3A53B77-445D-4C8B-8CF8-CF13247371AF @default.
- Q57580460 P2093 Q57580460-6952D02B-B074-40C6-8C54-7611AD20A66C @default.
- Q57580460 P2093 Q57580460-6B6B0271-C9C9-41EC-8887-145F1D080323 @default.
- Q57580460 P2093 Q57580460-A9A82375-6D27-4BCF-8F2A-9F4800DB8EC1 @default.
- Q57580460 P2093 Q57580460-B5D452F5-34A0-44E6-958D-97CEDEBA9215 @default.
- Q57580460 P2093 Q57580460-C2952247-083B-442C-BAF3-3DC739B9851D @default.
- Q57580460 P2093 Q57580460-D5F818B7-AECB-4405-A202-8BD3EA407C61 @default.
- Q57580460 P304 Q57580460-E61C450B-C4FA-4CE5-ABAC-55068743AD07 @default.
- Q57580460 P31 Q57580460-5F965534-BB1A-4623-B68B-78D578BC7E31 @default.
- Q57580460 P356 Q57580460-ECF36676-1163-4715-8E06-45959C1976DB @default.
- Q57580460 P407 Q57580460-BC59861F-E574-4759-9798-002CC017AAB2 @default.
- Q57580460 P433 Q57580460-E3B487A0-94E8-4EBF-BEC9-A329E0474068 @default.
- Q57580460 P478 Q57580460-2964DA1C-3820-4AA8-AD83-98D78E55D0BC @default.
- Q57580460 P50 Q57580460-0C093880-1E31-419B-B99C-853D88B38C71 @default.
- Q57580460 P50 Q57580460-11A19B80-E509-40E5-87FC-B5BA7C01E7BA @default.
- Q57580460 P50 Q57580460-25E2D448-1177-4CCE-A234-9645FEEE8FA1 @default.
- Q57580460 P50 Q57580460-3D8937E0-A604-4E93-A728-2C564A2DB652 @default.
- Q57580460 P50 Q57580460-58465261-C758-469A-9068-07A4CC9B1B4A @default.
- Q57580460 P50 Q57580460-5E81F3C3-C26C-4C79-9954-41FD2A8E9E18 @default.
- Q57580460 P50 Q57580460-67835BD9-CA94-496B-8E93-1B045F664EBD @default.
- Q57580460 P50 Q57580460-775E5C6A-4A28-4899-9669-A9DEF81D289C @default.
- Q57580460 P50 Q57580460-86149807-2EAD-4F31-AD58-CE100177965F @default.
- Q57580460 P50 Q57580460-D2AA3154-18C2-4595-9C8C-223EE5C3DE40 @default.
- Q57580460 P50 Q57580460-DDB782FE-03A9-48D8-81B4-77C8E010391A @default.
- Q57580460 P50 Q57580460-DFA79623-0ED6-482A-8F09-6A09DF6A4BE0 @default.
- Q57580460 P50 Q57580460-FC406C03-912B-428B-81E2-9A0E3D21DD8E @default.
- Q57580460 P577 Q57580460-64E819A3-866E-4208-8445-70CBB8CCB852 @default.
- Q57580460 P921 Q57580460-A49F7943-2145-42D8-B007-15712D5FB1A2 @default.
- Q57580460 P356 JCO.2017.35.15_SUPPL.9520 @default.
- Q57580460 P1433 Q400292 @default.
- Q57580460 P1476 "Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy" @default.
- Q57580460 P2093 "Carlos A. Gomez-Roca" @default.
- Q57580460 P2093 "Eva Muñoz-Couselo" @default.
- Q57580460 P2093 "Giuseppe Curigliano" @default.
- Q57580460 P2093 "Margaret K. Callahan" @default.
- Q57580460 P2093 "Matthew Maurer" @default.
- Q57580460 P2093 "Matthias Preusser" @default.
- Q57580460 P304 "9520-9520" @default.
- Q57580460 P31 Q13442814 @default.
- Q57580460 P356 "10.1200/JCO.2017.35.15_SUPPL.9520" @default.
- Q57580460 P407 Q1860 @default.
- Q57580460 P433 "15_suppl" @default.
- Q57580460 P478 "35" @default.
- Q57580460 P50 Q114426994 @default.
- Q57580460 P50 Q114522981 @default.
- Q57580460 P50 Q114523050 @default.
- Q57580460 P50 Q114523075 @default.
- Q57580460 P50 Q114523212 @default.
- Q57580460 P50 Q60525568 @default.
- Q57580460 P50 Q88123631 @default.
- Q57580460 P50 Q88137719 @default.
- Q57580460 P50 Q89457677 @default.
- Q57580460 P50 Q90321337 @default.
- Q57580460 P50 Q91043632 @default.
- Q57580460 P50 Q92037288 @default.
- Q57580460 P50 Q96194204 @default.
- Q57580460 P577 "2017-05-20T00:00:00Z" @default.
- Q57580460 P921 Q3421914 @default.